Tag Archives: Patent Law

A “Myriad” Of Questions To Resolve? Back To The Basics Of 101

Posted on May 18, 2010 by Warren Woessner

Thinking about Judge Sweet’s recent decision in Ass’n of Molecular Pathologists v. USPTO et al. (The “Myriad Decision”), I am again struck by the wide path the good judge slashed through the field (or is it the jungle now) of … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged bergy, biotechnology law, intellectual property, ip, Myriad, Myriad lawsuit, Patent Law, patents, Warren Woessner | Leave a comment

Director Kappos Comments on Ariad v. Lilly

Posted on May 6, 2010 by Warren Woessner

USPTO David Kappos recently posted a comment on the Fed. Cir. decision in Ariad v. Lilly in which he noted that the Fed. Cir. held that broad functional claims (presumably mechanism-of-action claims) must be supported by sufficient species (read “working examples”). While … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged Ariad v. Lilly, David Kappos, Patent Law, patents, USPTO, Warren Woessner | Leave a comment

Therasense To Be Re-Heard En Banc – “I Feel Your Pain”

Posted on April 28, 2010 by Warren Woessner

Monday’s decision by the Federal Circuit to vacate the split panel decision in Therasense, Inc. v. Becton Dickinson & Co., 593 F.3d 1289 (Fed. Cir. 2010) (link at end of post) and rehear the case en banc makes it impossible for … Continue reading →

Posted in Inequitable Conduct/Rule 56 | Tagged biotechnology, biotechnology law, biotechnology news, Federal Circuit, intellectual property, Patent Law, Therasense, Warren Woessner | Leave a comment

The Return Of The Magnificent Prosecution Specialists Or Just More “QA”?

Posted on April 15, 2010 by Warren Woessner

The USPTO recently announced the creation of an ombudsman program to resolve applicant/examiner logjams in all of the Tech Centers. This is a move that the Office (and practitioners) have needed badly for a number of years, ever since the … Continue reading →